These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 33157919)

  • 21. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
    Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
    Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical study on ixazomib in the treatment of multiple myeloma.
    He Y; Zhang K; Zou L; Chen S; Jiang D; Hu J; Zhu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):322-327. PubMed ID: 32386025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of ixazomib for the treatment of multiple myeloma.
    Bonnet A; Moreau P
    Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Terpos E; Politou M; Rahemtulla A
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
    Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
    Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
    Jouni H; Aubry MC; Lacy MQ; Vincent Rajkumar S; Kumar SK; Frye RL; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):220-221. PubMed ID: 27859518
    [No Abstract]   [Full Text] [Related]  

  • 35. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
    Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
    Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
    Parrondo RD; Alegria V; Roy V; Sher T; Chanan-Khan AA; Ailawadhi S
    Ann Hematol; 2021 Mar; 100(3):851-853. PubMed ID: 33161454
    [No Abstract]   [Full Text] [Related]  

  • 37. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
    Chang H; Lee SY; Tang TC
    Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
    Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
    J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
    Takakuwa T; Yamamura R; Ohta K; Kaneko H; Imada K; Nakaya A; Fuchida SI; Shibayama H; Matsuda M; Shimazu Y; Adachi Y; Kosugi S; Uchiyama H; Tanaka H; Hanamoto H; Shimura Y; Kanda J; Onda Y; Uoshima N; Yagi H; Yoshihara S; Hino M; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Kanakura Y; Nomura S
    Eur J Haematol; 2021 Apr; 106(4):555-562. PubMed ID: 33476404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
    Ludwig H; Poenisch W; Knop S; Egle A; Schreder M; Lechner D; Hajek R; Gunsilius E; Krenosz KJ; Petzer A; Weisel K; Niederwieser D; Einsele H; Willenbacher W; Melchardt T; Greil R; Zojer N
    Br J Cancer; 2019 Oct; 121(9):751-757. PubMed ID: 31558804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.